Ground-Glass Nodules on Chest CT as Imaging Biomarkers in the Management of Lung Adenocarcinoma

Cardiopulmonary Imaging Review Goo et al. Management of Lung denocarcinoma Cardiopulmonary Imaging Review FOCUS ON: Jin Mo Goo 1 Chang Min Park Hyun Ju Lee Goo JM, Park CM, Lee HJ Keywords: bronchioloalveolar carcinoma, CT, ground-glass opacity, lung cancer, nodule DOI:10.2214/JR.10.5813 Received September 6, 2010; accepted after revision December 22, 2010. 1 ll authors: Department of Radiology, Seoul National University College of Medicine, and Institute of Radiation Medicine, Seoul National University Medical Research Center, 101 Daehangno, Jongno-gu, Seoul 110-744, Korea. ddress correspondence to J. M. Goo (jmgoo@plaza.snu.ac.kr). JR 2011; 196:533 543 0361 803X/11/1963 533 merican Roentgen Ray Society Ground-Glass Nodules on Chest CT as Imaging iomarkers in the Management of Lung denocarcinoma OJECTIVE. The purpose of this article is to review the clinical significance of groundglass nodules (GGNs) in the management of lung adenocarcinoma. CONCLUSION. GGNs can serve as imaging biomarkers that represent the bronchioloalveolar carcinoma component in adenocarcinoma on histology and indicate a better prognosis in patients with lung adenocarcinoma. The evolution of GGNs reflects the multistep progression of adenocarcinoma. Despite the high probability of malignancy of GGNs, the possibility of overdiagnosis should be considered in the management of GGNs. denocarcinoma is the predominant type of lung cancer today, and its incidence has been reported to be increasing worldwide [1]. This rising prevalence has led to an evolution in our understanding of lung adenocarcinoma and related lesions, many of which appear as ground-glass opacities (GGOs) on chest CT. ackground One of the first important studies on pulmonary adenocarcinomas was published by Noguchi et al. [2] in 1995, in which they categorized small pulmonary adenocarcinomas into six groups based on histology. In their study, patients with bronchioloalveolar carcinoma (C) (type ) and C with foci of collapsed alveolar structures (type ) had a better 5-year survival rate (100%) than patients with C with a foci of active fibroblastic proliferation (type C, 75% survival rate) or patients with pure adenocarcinomas (types D F, 52% survival rate). ecause this classification proved to have good correlation with prognosis, in 1999 the World Health Organization (WHO) revised the classification of C as a noninvasive carcinoma with no evidence of stromal, vascular, or pleural invasion. Then, in the 2004 WHO classification, the term mixed subtype adenocarcinoma was introduced for tumors with invasion in association with a portion of the tumor having a replacement or lepidic growth pattern (C component). Jang et al. [3] first reported that Cs may be seen as GGOs, which are defined as hazy increased opacities of the lung with preser- vation of bronchial and vascular margins [4]. efore this study, GGOs had traditionally been regarded as areas of inflammation, hemorrhage, or fibrosis, but many studies have since confirmed that the GGO portion of the nodule corresponded to the C component of adenocarcinomas [5 7]. With the introduction of MDCT allowing volumetric acquisition of the whole lung using thin-section CT along with the increase of CT screening for lung cancer in asymptomatic subjects, the detection of ground-glass nodules (GGNs) [5, 8, 9], which are GGOs in nodular shape, was made with increasing frequency. GGNs detected on CT have been reported to comprise a wide range of diagnoses, from premalignant lesions, such as atypical adenomatous hyperplasia, or malignant lesions, such as C or adenocarcinoma. In a study dealing with the malignant potential of GGNs, the Early Lung Cancer ction Project [9] reported that the malignancy rate of GGNs (34%) was higher than that of solid nodules (7%) and that the malignancy rates of mixed GGNs (part-solid nodules) and pure GGNs (nonsolid nodules) were 64% and 18%, respectively. Individuals who have Cs on pathologic examination and who have GGNs on CT share many demographic findings; a higher percentage of women, a younger age distribution, and a higher incidence in never-smokers [10, 11]. The histologic features of Cs, which exhibit a lepidic growth pattern with proliferation of cells along the alveolar walls [12], also corresponded well with the CT features JR:196, March 2011 533

Goo et al. TLE 1: Pathologic Classifications, Pathologic Findings, CT Findings, and Prognosis of denocarcinoma Parameter Precursor Spectrum of denocarcinoma D, Poorly differentiated E, Tubular F, Papillary C, Localized C with active fibroblastic proliferation Noguchi type, Localized C, Localized C with alveolar collapse cinar adenocarcinoma, papillary adenocarcinoma, solid adenocarcinoma with mucin production World Health Organization 2004 H C C denocarcinoma with mixed subtype C (lepidic) vs invasive component None C component C component C and invasive component Invasive component Proportion of GGO on CT Pure GGO Pure GGO Pure or mixed GGO Pure or mixed GGO or solid Solid Prognosis Good Good Good In between ad Note C = bronchioloalveolar carcinoma, H = atypical adenomatous hyperplasia, GGO = ground-glass opacity. (dapted with permission from [76]) of GGOs. Thus, in this article, we review the various features of GGNs as seen on chest CT, with a special focus on their relationship with lung adenocarcinoma (Table 1). Technical Considerations in the CT cquisition of GGNs One of the first technical considerations in CT acquisition is slice thickness. It has been reported that with thick-section CT, solid nodules or even calcified nodules may mimic GGNs because of the partial volume effect [8] (Fig. 1). In a comparison study performed between 5- and 1-mm section CT images reconstructed from the same raw data, the assessment of nodule consistency was shown to be significantly different between the two scans [13]. In the assessment of GGNs, therefore, obtaining CT with a section thickness of 1.0 1.5 mm or less is essential. nother consideration is tube current. ccording to a recent study by Funama et al. [14], a low tube current may hinder the visibility of GGNs because of excessive noise. When the detectability of GGNs at low-dose CT was evaluated with the reference obtained at a standard dose of 180 ms, 39.5% and 25.8% of GGNs were missed at 21 and 45 ms, respectively. Therefore, a tube current of 50 ms or greater is recommended in the detection and follow-up of GGNs. Pathologic Correlation of GGNs Pathologically, GGNs can represent focal inflammation, focal fibrosis, atypical adenomatous hyperplasia, and C as well as adenocarcinoma [8, 10] (Table 2). mong these, atypical adenomatous hyperplasia, which is usually less than 5 mm in diameter and accompanied by the proliferation of type 2 pneumocyte-like or Clara cell-like cells with varied cellular atypia, is classified as a precursor lesion for lung adenocarcinoma according to the WHO classification. On CT, atypical adenomatous hyperplasia appears as a welldefined round or oval pure GGN [15] (Fig. 2) and is frequently found to be associated with adenocarcinoma, particularly C [5, 15]. CT features of GGNs correlate well with the histologic classification of adenocarcinoma proposed by Noguchi et al. [2], and the proportion of GGO in the GGN is significantly correlated with the C component of the adenocarcinoma-mixed subtype [5, 6, 16]. ccording to a study by Yang et al. [7], 94% of pure Cs (type ) were visualized as pure GGNs on CT (Fig. 3), whereas 71% of Cs with some alveolar wall collapse (type ) appeared as heterogeneous nodules with low attenuation. In addition, Cs with active fibroblastic foci (type C) appeared mostly as nodules with a GGO component in the periphery (29%) (Fig. 4) or as a solid nodule (50%). The solid component of a mixed GGN corresponded to areas of structural collapse of alveoli or fibroblastic proliferation [7]. Cs usually manifest as GGNs, whereas adenocarcinomas manifest as both solid nodules and GGNs [5] (Fig. 5). However, not all pure GGNs are Cs histologically, and they Fig. 1 43-year-old woman with pseudoground-glass nodule on thick-section low-dose CT., Chest CT scan of 5-mm section thickness shows 8-mm ground-glass nodule (arrow) without solid component in right lower lobe., Thin-section CT scan of 1-mm slice thickness reveals that lesion was not true ground-glass nodule but welldefined solid nodule (arrow). 534 JR:196, March 2011

Management of Lung denocarcinoma TLE 2: Common Lesions Manifesting as Ground- Glass Nodules (GGNs) Type of GGN Transient Persistent Lesion Inflammatory Focal hemorrhage Focal edema Focal fibrosis typical adenomatous hyperplasia ronchioloalveolar carcinoma denocarcinoma can have a component of invasive adenocarcinoma [17, 18]. In a study that evaluated the CT findings of 59 small adenocarcinomas, 94% of pure GGNs were of type or (C in the WHO classification), and 6% were type C lesions (adenocarcinoma with mixed subtype in the WHO classification) on the basis of the Noguchi classification [7] (Table 1). With an increase in the number of biopsies performed for GGNs, focal interstitial fibrosis is increasingly being detected as a cause. Radiologically, it appears as a persistent GGN and often shares the imaging features of neoplastic GGNs [8, 19, 20] (Fig. 6). On histologic examination, this lesion shows focal interstitial thickening with collagen fiber deposition and type 2 pneumocyte proliferation as well as macrophage collection in the airspace [19, 20]. The clinical significance of GGNs in patients with extrapulmonary cancers was evaluated in a study by Park et al. [21]. In their report, 82.4% of patients and 67.8% of GGNs were diagnosed as malignancies, none of which were metastatic. However, because primary adenocarcinomas and Cs manifesting as GGNs typically show slow growth, when GGNs show rapid growth in patients with extrapulmonary cancers, metastasis or inflammatory lesions should be considered. The differentiation of benign from malignant persistent GGNs can often be difficult Fig. 3 54-year-old woman with bronchioloalveolar carcinoma appearing as pure ground-glass nodule in right lower lobe., Thin-section CT scan at level of right main pulmonary artery shows 10-mm well-defined pure ground-glass nodule (arrow) in right lower lobe., Photomicrograph shows alveolar lining replacement by columnar neoplastic epithelium without evidence of stromal invasion. (H and E, 100) Fig. 2 54-year-old woman with atypical adenomatous hyperplasia., Thin-section CT scan at level of aortopulmonary window shows 7-mm well-defined pure ground-glass nodule (arrow) in left upper lobe., Photomicrograph shows thickened alveolar walls lined by single layer of atypical cuboidal pneumocytes. (H and E, 100) [22] because focal interstitial fibrosis shares many morphologic features with malignant GGNs. However, the presence and proportion of a solid portion within a GGN can be an important predictor of malignancy [9, 21, 23]. In the differentiation of C from atypical adenomatous hyperplasia, which sometimes manifests as pure GGN, one study showed that sphericity (visually assessed roundness in this study) was significantly associated with atypical adenomatous hyperplasia, whereas air bronchograms were associated with C [24]. In addition, it was suggested by Nakata et al. [23] that a threshold of 10 mm could be a significant sign of malignancy, with more recent studies suggesting a threshold of 8 mm in differentiating benign from malignant lesions for pure GGNs through receiver operating characteristic analysis [25, 26]. However, some overlaps between the two entities still remain. ccording to the results of Lee et al. [25], when pure GGNs and mixed GGNs were assessed separately, significant predictive CT findings of malignancy were a size of > 8 mm for pure GGNs and a lobulated border for both pure and mixed GGNs. Molecular ackground of Lung denocarcinoma Molecular changes in lung carcinoma include mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene, amplifications of the EGFR genes, and activation of mutations of the K-ras gene. novel therapeutic approach targeting EGFR, such as EGFR-tyrosine kinase inhibi- JR:196, March 2011 535

Goo et al. tors (TK inhibitors) including gefitinib and erlotinib has been extensively studied. In these studies, non small cell lung cancer (NSCLC) patients with EFGR mutations were reported to show excellent response to EGFR-TK inhibitors, and EGFR mutations were more frequently found in patients with adenocarcinoma histology, female sex, never-smokers, and East sian ethnicity [27, 28]. When EGFR mutation status was correlated with the types of lung adenocarcinoma according to the Noguchi classification, the mutation was preferentially found in adenocarcinoma with a replacing growth (types C) compared with adenocarcinomas of types D F [27]. These results suggest that adenocarcinomas of types C may arise through different mechanisms. Furthermore, although some reports have indicated that EGFR mutations are associated frequently with adenocarcinomas with C features [27, 29, 30], another report has suggested that C features are not absolute determinants for EGFR mutations [31]. ecause Cs are closely related with GGNs on CT, the association of GGNs on CT with EGFR and K-ras mutations has also been investigated. However, according to a recent study by Glynn et al. [32], the presence of GGO within a nodule was not shown to be associated with EGFR or K-ras mutations. Increased EGFR gene copy number, as assessed by a fluorescence in situ hybridization Fig. 4 67-year-old man with bronchioloalveolar carcinoma manifesting as mixed ground-glass nodule in right middle lobe., Thin-section CT scan obtained at level of left atrium shows 18-mm mixed ground-glass nodule (arrow) in right middle lobe. We can identify presence of internal solid portion within lesion., Photomicrograph shows replacement-type tumor growth and foci of fibroblastic proliferations and alveolar collapse (arrowheads). (H and E, 40) (FISH) assay, on the other hand, was associated with lymph node metastasis, more advanced pathologic stage, and poor prognosis [33]. In a study in which FISH-positive was defined as a tumor showing high polysomy or gene amplification, a high maximum standardized uptake value (SUV) on 18 F-FDG PET was significantly related to FISH-positive results, whereas a high proportion of GGO, small tumor diameter on CT, and well-differentiated histopathology were more frequent in FISH-negative adenocarcinomas [34]. This field is under active research, and understanding molecular biomarkers in combination with imaging findings would be essential in the management of lung adenocarcinoma. Evolution of GGNs Most inflammatory lesions and focal hemorrhage, which manifest as GGNs, disappear at short-term follow-up (Fig. 7). t screening settings, it has been reported that 37 70% of GGNs can resolve spontaneously or after appropriate treatment over several weeks or months [35 37]. Patient and nodule characteristics of these transient GGNs include young patient age, detection of lesion at follow-up, blood eosinophilia, lesion multiplicity, large solid portion, ill-defined border, and polygonal shape [35 37]. Persistent GGNs, on the other hand, can signify a wider range of diagnoses, including focal interstitial fibrosis, atypical adenomatous hyperplasia, C, or adenocarcinoma [22]. The natural progression of GGNs has been shown in several serial CT studies with follow-up. The evolving features of GGNs on Fig. 5 60-year-old woman with adenocarcinoma with mixed acinar and bronchioloalveolar carcinoma (C) pattern., Thin-section CT scan obtained at level of main pulmonary artery shows 20-mm well-defined mixed groundglass nodule (arrow) with peripheral ground-glass opacity in left lower lobe., Photomicrograph shows replacement-type tumor growth representative of C pattern in periphery of tumor. (H and E, 40) 536 JR:196, March 2011

Management of Lung denocarcinoma [33], and EGFR amplification is superimposed on the progression to invasive cancer. serial CT that suggest malignancy include an overall increase in the size of a GGN, development of a solid component within a GGN, or an increase in the solid component of a GGN (Fig. 8). Stable size with increasing attenuation of a GGN could also be a sign of malignancy [38]. study by Takashima et al. [39] showed that lung adenocarcinomas that initially presented as GGNs subsequently increased in size in 75% of cases, developed solid components within the nodule in 17%, and showed an increase in the solid portion in 23% of cases. Some GGNs, which are proven to be malignancies on histologic examination, do not change in size [17, 40]. In one study involving 19 patients, the size of pure GGNs did not change in eight of the patients during a followup of 2 years or more, and the authors suggested that some pure GGNs would never progress to a clinical disease [40]. In another study, Kakinuma et al. [38] reported a rare finding of decreasing size with the appearance of a solid component in one C and one adenocarcinoma with mixed subtype. This decrease in size in the course of follow-up, however, was explained by the collapse or severe narrowing of alveolar space or fibrosis [38]. When GGNs are persistent at 3-month follow-up, GGNs larger than 10 mm and patients with a history of lung cancer are reported to be higher risk factors for GGN growth [41]. In addition, compared with pure GGNs, mixed GGNs show interval growth more frequently and usually turn out to be adenocarcinomas [17]. Fig. 6 51-year-old woman with focal interstitial fibrosis., Thin-section CT scan at level of left innominate vein shows 9-mm well-defined pure ground-glass nodule (arrow) in left upper lobe., High-power photomicrograph shows lesion consists of interstitial thickening with fibrosis of alveolar wall and intraalveolar hemorrhage. (H and E, 200) The multistep progression of lung adenocarcinoma in which a precursor or premalignant lesion of atypical adenomatous hyperplasia progresses to C followed by invasive adenocarcinoma has previously been proposed [2], and more recently, the molecular background of this stepwise progression has been suggested [31]. In this concept, EGFR mutations contribute in the early stage of lung adenocarcinoma development Prognostic Value of Ground-Glass Nodularity in Lung denocarcinoma The proportion of the C component in lung adenocarcinoma is known to be a positive prognostic factor [16]. high non-c component has been strongly associated with both recurrence and poor prognosis in patients with lung adenocarcinoma [42]. It was further suggested that adenocarcinoma with greater than 90% C component might be considered minimally invasive [16]. s expected from the correlation between the proportion of C component and CT consistency, the relative proportion of GGO correlates well with recurrence, vascular invasion, nodal metastasis, and survival [6, 43 48]. When various clinical, CT, and pathologic parameters were evaluated for the determination of prognostic significance in lung adenocarcinoma, lesion size, percentage of GGO area, and tumor subtypes were significant on univariate analyses, whereas the percentage of GGO area was the only independent prognostic factor according to multivariate analyses [49]. Tumor size is considered one of the determinants in staging; however, tumor size alone is not able to indicate the invasive or noninvasive nature of lung adenocarcinomas. Indeed, it was shown that small adenocarcinomas even 1 cm Fig. 7 51-year-old man with transient ground-glass nodule., Thin-section CT scan at level of right upper lobe bronchus shows 12-mm mixed ground-glass nodule (arrow) in right upper lobe., Follow-up thin-section CT scan obtained 2 months later shows disappearance of this mixed ground-glass nodule seen in. JR:196, March 2011 537

Goo et al. or less in diameter can show lymph node metastasis. In a study by Ohta et al. [50], four of 11 patients with adenocarcinomas 1 cm in diameter showed lymph node metastasis. better indicator for the prediction of the noninvasive nature of lung adenocarcinoma may be the GGO proportion of a tumor. When the combined effects of GGO proportion and tumor size were compared, stage I disease with a GGO proportion 50% showed a higher 5-year relapsefree survival rate than stage I disease with a GGO proportion of < 50% [51]. s to the question of whether GGNs detected on chest CT can be safely followed up without immediate biopsy or surgical resection, Sawada et al. [52] reported that it can. In their study, follow-up CT examinations were performed at an interval of 3 12 months for both pure and mixed GGNs until the authors had detected either lesion growth or a new solid portion. They found that such followup did not lead to either treatment delays or negative influence on patient outcome. Fig. 8 Progression of ground-glass nodule showing size increase and solid component formation in 62-yearold man with adenocarcinoma., Initial thin-section CT scan at level of aortic arch shows 13-mm ill-defined ground-glass nodule in left upper lobe., On follow-up CT scan obtained 34 months later, this lesion definitely increases in size and has internal solid components. Patient underwent left upper lobectomy, and pathologic examination revealed that this lesion was adenocarcinoma. iopsy and Surgical Treatment of GGNs Pathology for persistent GGNs can be established either through CT-guided biopsy or surgical biopsy. The diagnostic yield for CTguided fine-needle biopsy for GGNs was reported to be 64.5% and that for GGNs with a GGO proportion > 50% was 51.2% [53]. CT-guided core biopsy showed better results: sensitivity of 92% and specificity of 90% after seven of 50 lesions were excluded from the calculation because of loss to follow-up or nondiagnostic samples [54]. It is impossible to make an unequivocal diagnosis of C in small biopsy specimens because only the C component may be biopsied in patients with adenocarcinoma with mixed C. If the suspicion for malignancy of a persistent GGN is high on CT or if there is any increase in size or solid portion of GGN, CT-guided biopsy may be bypassed and surgical biopsy can be performed to obtain a pathologic diagnosis. On the basis of a randomized trial by the Lung Cancer Study Group, the standard procedure for T1N0 NSCLC is lobectomy with mediastinal lymph node dissection [55]. For the surgical treatment of peripheral lung adenocarcinoma manifesting as a pure GGN, however, limited wedge resection without lymph node dissection rather than standard lobectomy has been suggested and conducted by many Japanese investigators. For the mean follow-up period of 2 5 years, when limited resections were performed in patients with pure or predominantly pure GGNs, no intrathoracic recurrence or distant metastasis was observed [56 58]. The sample sizes were relatively small, the patients were not randomized, and invasive cancers cannot be excluded with CT findings alone; however, the studies do suggest that the favorable prognosis of GGNs may justify limited resection. Role of PET in the Evaluation of GGNs In comparison with solid nodules, FDG PET has limited value in the evaluation of GGNs for determining nodule malignancy and staging. Kim et al. [59] reported a high false-negative rate of FDG PET for identifying C (Fig. 9). In another study, Chun et al. [60] compared the maximum SUV of malignancy and inflammation that manifested as GGN on CT. Interestingly, in mixed GGNs, the maximum SUV was significantly higher in inflammatory lesions (2.00 ± 1.18) than in malignancies (1.26 ± 0.71), but in pure GGNs, both inflammation and malignancy showed an SUV less than 1.0 and did not show a difference. Quantitative nalysis and Computer-ssisted Schemes Detecting GGNs is not an easy task because of their low contrast to the background lung. In a study by Li et al. [61], 69% of lung cancers missed by radiologists at screening CT were GGNs. Thus, automated computer-aided detection (CD) schemes for GGNs have been investigated and the first CD scheme for automated detection of GGNs was reported by Kim et al. [62] using texture features and gaussian curve fitting features. More recently, Yanagawa et al. [63] evaluated the performance of a commercial CD system in the detection of GGNs, but unfortunately, to date, the CD system can only play a complementary role in the detection of GGNs. Various approaches have been made to evaluate the change of GGNs over time. One approach of particular note is computer-assisted volumetry, which has shown improved reproducibility in measuring solid nodules. When computer-aided volumetry was applied to GGNs 8 mm or larger, 95% limits of intraobserver agreement were up to 14.9 16.6% in measuring the same nodule and those of interobserver agreement were up to 23.7% [64]. The interscan variability of nodule volumetry for GGNs using a same-day repeat CT study was reported to be up to 18.9% [65]. To reflect the changes in GGNs not only in size but also in attenuation, another approach in determining the growth of GGNs has been proposed. 538 JR:196, March 2011

Management of Lung denocarcinoma In a phantom study by Lee et al. [66], the calculated amount of soft tissue in a nodule, [volume (1 + mean attenuation value / 1,000)], showed a strong correlation with the reference standard amount of soft tissue. In a clinical evaluation, de Hoop et al. [67] applied a similar method of GGN mass measurement, and this method showed the smallest measurement variability thus far compared with diameter and volume measurements, meaning that the growth of a GGN can be detected earlier with mass measurements. ecause the GGO component in GGNs is one of the most important prognostic factors, various methods to measure the proportion of GGO have also been investigated through manual measurement of the diameter or area of a nodule and the solid component of a nodule [43, 45, 47, 48]. nother method of measuring GGO proportion is through the vanishing ratio or tumor shadow disappearance rate, which is defined as the ratio between GGN size measured at lung window settings and at mediastinal window settings. This ratio was shown to correlate better with 5-year relapsefree survival than other measurements using either length or area [68]. When a commercial automated program able to segment the solid area from a GGO area was compared with manual measurement methods, the measurement using software showed better interobserver agreements but worse correlation with histology on the basis of the Noguchi classification of adenocarcinoma [69]. Fig. 9 61-year-old woman with adenocarcinoma with mixed acinar and bronchioloalveolar pattern., Thin-section CT scan at level of left ventricle of heart shows 17-mm ground-glass nodule (arrow) in left lower lobe., On 18 F-FDG PET/CT image, this nodule (arrow) shows mild FDG uptake, and maximum standardized uptake value of nodule was measured as 1.80. In measuring the size and solid portion of a GGN, investigators need to consider the dimension of measurements (length, area, or volume); section thickness of the CT scan; and thresholds for lesion boundary, which can be determined by window settings on visual assessment [70]. Several reports have shown that the tumor shadow disappearance rate had better correlation with the C proportion or prognosis than the GGO proportion determined at lung window settings [6, 68]. This indicates that the solid portion in GGNs on CT can be determined better at mediastinal window settings. Therefore, applying an adequate threshold is necessary to produce better parameters that correlate with pathologic examination and to predict the prognosis. Multifocal GGNs GGNs frequently manifest as multifocal lesions in the lung. In a study by Vazquez et al. [16], nonsolitary cancers were seen in 49 (18%) of 279 resected adenocarcinomas. These synchronous multifocal lung GGNs may be due to either intrapulmonary metastasis or synchronous primary cancers and raise a staging dilemma. The problem also extends to whether systemic chemotherapy or surgical resection should be administered. Furthermore, when a pure GGN is present in patients with otherwise operable NSCLC, controversy exists as to whether these lesions should be resected along with the primary tumor. Several studies have attempted to answer these questions and found that most of the small node-negative multiple carcinomas probably represent multiple primaries rather than intrapulmonary metastasis [16, 26]. Thus, they found that multifocal lesions may be amenable to surgical resection with prolonged survival and that their presence in resected cases did not impact the prognosis [16]. One study by Kim et al. [26] further suggested that pure GGNs 8 mm should be resected to rule out the possibility of malignancy, whereas pure GGNs < 8 mm could be closely followed using CT. When clinical, pathologic, and thin-section CT features were compared between multiple GGNs and solitary GGNs [71], atypical adenomatous hyperplasias and Cs were more frequent in multiple GGNs (Fig. 10), whereas adenocarcinomas were more frequent in solitary GGNs. Those authors also found that multiple GGNs were more frequently found in women and nonsmokers and were smaller than solitary GGNs. In addition, on CT, solitary GGNs showed air bronchogram, bubble-lucency, and pleural retraction more frequently. In a molecular investigation, Chung et al. [72] analyzed the clonal relationship between multiple GGNs using EGFR and K- ras mutational profiles. In this study, 18 of 24 patients had different clonality of multiple GGNs, suggesting that these lesions arise as independent events rather than intrapulmonary spread or metastasis. However, the multifocal GGNs discussed in this section should not be confused with multiple GGOs, which can sometimes occur in combination with airspace pattern malignancy, because such cases have a worse prognosis compared with the cases dealt with in this section. Fig. 10 64-year-old woman with multiple groundglass nodules. Thin-section CT scan at level of aortic arch shows multiple variable-sized ground-glass nodules in both lungs. Dominant nodule among these lesions was resected and was pathologically confirmed as bronchioloalveolar carcinoma. JR:196, March 2011 539

Goo et al. Potential for Overdiagnosis ecause most GGNs show a slow growth rate despite their high potential for malignancy, the issue of overdiagnosis, which is the diagnosis of a disease that will never cause symptoms or death during a patient s lifetime, remains a problem in the management of patients with GGNs. Cancers detected at baseline screening have been reported to be more slow growing than those detected on repeat examinations, and cancers presenting as GGNs were more frequent at baseline rather than repeat screening [5]. In another study, Hasegawa et al. [73] reported that the mean volume doubling time of pure GGNs was 813 ± 375 days and that of mixed GGNs was 457 ± 260 days, whereas the mean volume doubling time of solid nodules was 149 ± 125 days. Considering the standard of 400 days for overdiagnosis proposed by Yankelevitz et al. [74], 27 of 61 cancers included in the study by Hasegawa et al. can be considered as cases of overdiagnosis. In a study by Lindell et al. [75], 13 of 48 cancers, including 23 GGNs and 25 solid nodules, had a volume doubling time longer than 400 days, although nodule consistency was assessed using 5-mm-thick CT scans in that study. They also stressed that the majority of possibly overdiagnosed cancers occurred in women. In addition, all pure GGNs, which were not only Cs but also adenocarcinomas, showed a 2-year relapse-free survival [18]. ecause GGNs, especially pure GGNs, have a potential for overdiagnosis, physicians should consider whether the benefit from surgical resection of malignant GGNs outweighs the potential adverse effects of surgery in older patients, especially those with comorbidity. Suggested Guidelines in the Management of GGNs Several guidelines have been suggested in the management of GGNs on the basis of CT findings. Recently, Godoy et al. [76] proposed interim guidelines in terms of size and nodule consistency, which can be summarized as follows: Isolated pure GGNs smaller than 5 mm in size do not need follow-up CT studies. Pure GGNs between 5 and 10 mm in size require initial follow-up in 3 6 months to confirm persistence, with continued long-term followup for persistent GGNs. Persistent pure GGNs 10 mm or larger in size, any mixed GGNs, and growing GGNs should be resected. Finally, multiple GGNs can be managed through limited surgical resection for dominant lesions. In another study, samura [11] recommended a minimally invasive approach for lung adenocarcinomas that manifested as GGNs: Pure GGNs with a diameter of less than 15 mm can be monitored carefully without intervention, with overt growth or an overt solid portion being an indication for surgical intervention; and pure GGNs larger than 15 mm in diameter or mixed GGNs less than 15 mm in diameter should be managed through wide resection or segmentectomy provided they are located in the outer one third of the lung parenchyma or through standard lobectomy if tumors show overt invasive growth or predominantly solid GGNs. On the basis of previous guidelines and literature regarding the management of incidentally detected GGNs, recommendations for follow-up and intervention of GGNs are presented in ppendix 1. Summary and Future Issues Conventionally, lung cancer is closely related to smoking and occurs more commonly in older men. However, there appears to be another type of distinctive lung cancer with a relatively slow growth rate that can be characterized clinically as having a more common occurrence in women and nonsmokers. Pathologically, it is often accompanied by a C component. GGNs on CT share these characteristics, and thus can serve as imaging biomarkers that represent the C component of adenocarcinoma on histology and indicate a better prognosis of lung adenocarcinoma. Yet, there are still discrepancies between nodule consistency on CT and the histologic subtype of adenocarcinoma described in the literature, and therefore prognosis cannot be determined at present with CT features alone. Recent research has indicated that molecular biomarkers, such as EGFR mutations, are closely related to these cancers and newly developed targeted therapy may be able to use this information for personalized treatment. To that end, the molecular background of the multistep progression of adenocarcinoma is under active research today. In the clinical setting, despite the high probability of malignancy of GGNs, the issue of overdiagnosis should be considered in the management of GGNs. Thus, in addition to size and nodule consistency, growth rate needs to be considered for surgical treatment especially in elderly individuals with comorbid conditions. In the near future, robust quantifying schemes, providing objective standards able to detect the change in size of GGNs and the proportion of the solid portion of GGNs must be developed because pure GGNs as well as mixed GGNs with a predominant GGO component have been shown to provide better prognosis than lung cancer manifesting as solid nodules. References 1. Charloux, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997; 26:14 23 2. Noguchi M, Morikawa, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer 1995; 75: 2844 2852 3. Jang HJ, Lee KS, Kwon OJ, Rhee CH, Shim YM, Han J. ronchioloalveolar carcinoma: focal area of ground-glass attenuation at thin-section CT as an early sign. Radiology 1996; 199:485 488 4. Hansell DM, ankier, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246:697 722 5. Carter D, Vazquez M, Flieder D, et al. Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening. Lung Cancer 2007; 56:193 199 6. Okada M, Nishio W, Sakamoto T, et al. Correlation between computed tomographic findings, bronchioloalveolar carcinoma component, and biologic behavior of small-sized lung adenocarcinomas. J Thorac Cardiovasc Surg 2004; 127:857 861 7. Yang ZG, Sone S, Takashima S, et al. High-resolution CT analysis of small peripheral lung adenocarcinomas revealed on screening helical CT. JR 2001; 176:1399 1407 8. Park CM, Goo JM, Lee HJ, Lee CH, Chun EJ, Im JG. Nodular ground-glass opacity at thin-section CT: histologic correlation and evaluation of change at follow-up. RadioGraphics 2007; 27: 391 408 9. Henschke CI, Yankelevitz DF, Mirtcheva R, McGuinness G, McCauley D, Miettinen OS. CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. JR 2002; 178:1053 1057 10. Gandara DR, berle D, Lau D, et al. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol 2006; 1[9 suppl]:s20 S26 11. samura H. Minimally invasive approach to early, peripheral adenocarcinoma with ground-glass opacity appearance. nn Thorac Surg 2008; 85: S701 S704 12. Travis WD, Garg K, Franklin W, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bron- 540 JR:196, March 2011

Management of Lung denocarcinoma chioloalveolar carcinoma. J Clin Oncol 2005; 23: 3279 3287 13. Lee HY, Goo JM, Lee HJ, et al. Usefulness of concurrent reading using thin-section and thicksection CT images in subcentimetre solitary pulmonary nodules. Clin Radiol 2009; 64:127 132 14. Funama Y, wai K, Liu D, et al. Detection of nodules showing ground-glass opacity in the lungs at low-dose multidetector computed tomography: phantom and clinical study. J Comput ssist Tomogr 2009; 33:49 53 15. Park CM, Goo JM, Lee HJ, et al. CT findings of atypical adenomatous hyperplasia in the lung. Korean J Radiol 2006; 7:80 86 16. Vazquez M, Carter D, rambilla E, et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer 2009; 64:148 154 17. Lee HJ, Goo JM, Lee CH, Yoo CG, Kim YT, Im JG. Nodular ground-glass opacities on thin-section CT: size change during follow-up and pathological results. Korean J Radiol 2007; 8:22 31 18. Park JH, Lee KS, Kim JH, et al. Malignant pure pulmonary ground-glass opacity nodules: prognostic implications. Korean J Radiol 2009; 10: 12 20 19. Park CM, Goo JM, Lee HJ, et al. Focal interstitial fibrosis manifesting as nodular ground-glass opacity: thin-section CT findings. Eur Radiol 2007; 17:2325 2331 20. Hara M, Oda K, Ogino H, et al. Focal fibrosis as a cause of localized ground glass attenuation (GG): CT and MR findings. Radiat Med 2002; 20:93 95 21. Park CM, Goo JM, Kim TJ, et al. Pulmonary nodular ground-glass opacities in patients with extrapulmonary cancers: what is their clinical significance and how can we determine whether they are malignant or benign lesions? Chest 2008; 133: 1402 1409 22. Kim HY, Shim YM, Lee KS, Han J, Yi C, Kim YK. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology 2007; 245:267 275 23. Nakata M, Saeki H, Takata I, et al. Focal groundglass opacity detected by low-dose helical CT. Chest 2002; 121:1464 1467 24. Oda S, wai K, Liu D, et al. Ground-glass opacities on thin-section helical CT: differentiation between bronchioloalveolar carcinoma and atypical adenomatous hyperplasia. JR 2008; 190:1363 1368 25. Lee HJ, Goo JM, Lee CH, et al. Predictive CT findings of malignancy in ground-glass nodules on thin-section chest CT: the effects on radiologist performance. Eur Radiol 2009; 19:552 560 26. Kim HK, Choi YS, Kim K, et al. Management of ground-glass opacity lesions detected in patients with otherwise operable non-small cell lung cancer. J Thorac Oncol 2009; 4:1242 1246 27. Haneda H, Sasaki H, Shimizu S, et al. Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Lung Cancer 2006; 52:47 52 28. Shigematsu H, Gazdar F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118:257 262 29. Miller V, Kris MG, Shah N, et al. ronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmall-cell lung cancer. J Clin Oncol 2004; 22:1103 1109 30. lons H, Cote JF, Le Corre D, et al. Epidermal growth factor receptor mutation in lung cancer linked to bronchioloalveolar differentiation. m J Surg Pathol 2006; 30:1309 1315 31. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010; 29:23 36 32. Glynn C, Zakowski MF, Ginsberg MS. re there imaging characteristics associated with epidermal growth factor receptor and KRS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol 2010; 5:344 348 33. Soh J, Toyooka S, Ichihara S, et al. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol 2008; 3:340 347 34. Park E, Lee HJ, Kim YT, et al. EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology. Lung Cancer 2009; 64:179 186 35. Felix L, Serra-Tosio G, Lantuejoul S, et al. CT characteristics of resolving ground-glass opacities in a lung cancer screening programme. Eur J Radiol [Epub 2009 Oct 3] 36. Lee SM, Park CM, Goo JM, et al. Transient partsolid nodules detected at screening thin-section CT for lung cancer: comparison with persistent part-solid nodules. Radiology 2010; 255:242 251 37. Oh JY, Kwon SY, Yoon HI, et al. Clinical significance of a solitary ground-glass opacity (GGO) lesion of the lung detected by chest CT. Lung Cancer 2007; 55:67 73 38. Kakinuma R, Ohmatsu H, Kaneko M, et al. Progression of focal pure ground-glass opacity detected by low-dose helical computed tomography screening for lung cancer. J Comput ssist Tomogr 2004; 28:17 23 39. Takashima S, Maruyama Y, Hasegawa M, et al. CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern. JR 2003; 180:817 826 40. Kodama K, Higashiyama M, Yokouchi H, et al. Natural history of pure ground-glass opacity after long-term follow-up of more than 2 years. nn Thorac Surg 2002; 73:386 392; discussion, 392 393 41. Hiramatsu M, Inagaki T, Matsui Y, et al. Pulmonary ground-glass opacity (GGO) lesions: large size and a history of lung cancer are risk factors for growth. J Thorac Oncol 2008; 3:1245 1250 42. Kobayashi N, Toyooka S, Ichimura K, et al. Non- C component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung. J Thorac Oncol 2008; 3:704 710 43. oki T, Tomoda Y, Watanabe H, et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology 2001; 220:803 809 44. Kim E, Johkoh T, Lee KS, et al. Quantification of ground-glass opacity on high-resolution CT of small peripheral adenocarcinoma of the lung: pathologic and prognostic implications. JR 2001; 177:1417 1422 45. Matsuguma H, Yokoi K, nraku M, et al. Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: a predictor of lymph node metastasis. J Thorac Cardiovasc Surg 2002; 124:278 284 46. Nakata M, Sawada S, Yamashita M, et al. Objective radiologic analysis of ground-glass opacity aimed at curative limited resection for small peripheral non-small cell lung cancer. J Thorac Cardiovasc Surg 2005; 129:1226 1231 47. Nishio R, kata S, Saito K, et al. The ratio of the maximum high attenuation area dimension to the maximum tumor dimension may be an index of the presence of lymph node metastasis in lung adenocarcinomas 3 cm or smaller on high-resolution computed tomography. J Thorac Oncol 2007; 2:29 33 48. Ohde Y, Nagai K, Yoshida J, et al. The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma. Lung Cancer 2003; 42:303 310 49. Takashima S, Maruyama Y, Hasegawa M, et al. Prognostic significance of high-resolution CT findings in small peripheral adenocarcinoma of the lung: a retrospective study on 64 patients. Lung Cancer 2002; 36:289 295 50. Ohta Y, Oda M, Wu J, et al. Can tumor size be a guide for limited surgical intervention in patients with peripheral non-small cell lung cancer? ssessment from the point of view of nodal micrometastasis. J Thorac Cardiovasc Surg 2001; 122: 900 906 JR:196, March 2011 541

Goo et al. 51. Seki N, Sawada S, Nakata M, et al. Lung cancer nary ground-glass nodules: the feasibility of inte- nonsmall cell lung cancer: a multicenter study. J with localized ground-glass attenuation repre- grated (18)F-FDG PET/CT. Lung Cancer 2009; Comput ssist Tomogr 2008; 32:792 798 sents early-stage adenocarcinoma in nonsmokers. 65:180 186 69. Sumikawa H, Johkoh T, Nagareda T, et al. Pulmo- J Thorac Oncol 2008; 3:483 490 61. Li F, Sone S, be H, MacMahon H, rmato SG nary adenocarcinomas with ground-glass attenua- 52. Sawada S, Komori E, Nogami N, Segawa Y, 3rd, Doi K. Lung cancers missed at low-dose heli- tion on thin-section CT: quantification by three- Shinkai T, Yamashita M. Evaluation of lesions cal CT screening in a general population: com- dimensional image analyzing method. Eur J corresponding to ground-glass opacities that were resected after computed tomography follow-up examination. Lung Cancer 2009; 65:176 179 53. Shimizu K, Ikeda N, Tsuboi M, Hirano T, Kato H. Percutaneous CT-guided fine needle aspiration for lung cancer smaller than 2 cm and revealed by ground-glass opacity at CT. Lung Cancer 2006; 51:173 179 54. Kim TJ, Lee JH, Lee CT, et al. Diagnostic accuracy of CT-guided core biopsy of ground-glass opacity pulmonary lesions. JR 2008; 190:234 239 55. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer: Lung Cancer Study Group. nn Thorac Surg 1995; 60:615 622; discussion, 622 613 56. Nakamura H, Saji H, Ogata, Saijo T, Okada S, Kato H. Lung cancer patients showing pure ground-glass opacity on computed tomography are good candidates for wedge resection. Lung Cancer 2004; 44:61 68 57. Sugi K, Kobayashi S, Sudou M, Sakano H, Matsuda E, Okabe K. Long-term prognosis of videoassisted limited surgery for early lung cancer. Eur J Cardiothorac Surg 2010; 37:456 460 58. Yoshida J, Nagai K, Yokose T, et al. Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg 2005; 129:991 996 59. Kim T, Kim Y, Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. JR 1998; 170:935 939 60. Chun EJ, Lee HJ, Kang WJ, et al. Differentiation between malignancy and inflammation in pulmo- parison of clinical, histopathologic, and imaging findings. Radiology 2002; 225:673 683 62. Kim KG, Goo JM, Kim JH, et al. Computer-aided diagnosis of localized ground-glass opacity in the lung at CT: initial experience. Radiology 2005; 237:657 661 63. Yanagawa M, Honda O, Yoshida S, et al. Commercially available computer-aided detection system for pulmonary nodules on thin-section images using 64 detectors-row CT: preliminary study of 48 cases. cad Radiol 2009; 16:924 933 64. Oda S, wai K, Murao K, et al. Computer-aided volumetry of pulmonary nodules exhibiting ground-glass opacity at MDCT. JR 2010; 194: 398 406 65. Park CM, Goo JM, Lee HJ, Kim KG, Kang MJ, Shin YH. Persistent pure ground-glass nodules in the lung: interscan variability of semiautomated volume and attenuation measurements. JR 2010; 195:1315; [web]w408 W414 66. Lee KW, Im JG, Kim TJ, Dae CM. new method of measuring the amount of soft tissue in pulmonary ground-glass opacity nodules: a phantom study. Korean J Radiol 2008; 9:219 225 67. de Hoop, Gietema H, van Ginneken, Zanen P, Groenewegen G, Prokop M. comparison of six software packages for evaluation of solid lung nodules using semi-automated volumetry: what is the minimum increase in size to detect growth in repeated CT examinations? Eur Radiol 2009; 19:800 808 68. Kakinuma R, Kodama K, Yamada K, et al. Performance evaluation of 4 measuring methods of ground-glass opacities for predicting the 5-year relapse-free survival of patients with peripheral Radiol 2008; 65:104 111 70. Goo JM, Tongdee T, Tongdee R, Yeo K, Hildebolt CF, ae KT. Volumetric measurement of synthetic lung nodules with multi-detector row CT: effect of various image reconstruction parameters and segmentation thresholds on measurement accuracy. Radiology 2005; 235:850 856 71. Kim TJ, Goo JM, Lee KW, Park CM, Lee HJ. Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. Lung Cancer 2009; 64:171 178 72. Chung JH, Choe G, Jheon S, et al. Epidermal growth factor receptor mutation and pathologic radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol 2009; 4:1490 1495 73. Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. r J Radiol 2000; 73:1252 1259 74. Yankelevitz DF, Kostis WJ, Henschke CI, et al. Overdiagnosis in chest radiographic screening for lung carcinoma: frequency. Cancer 2003; 97: 1271 1275 75. Lindell RM, Hartman TE, Swensen SJ, et al. Fiveyear lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology 2007; 242: 555 562 76. Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology 2009; 253:606 622 (ppendix follows on next page) 542 JR:196, March 2011